Nomogram for predicting long-term survival in renal cell carcinoma patients undergoing thermal ablation.

IF 2.4 3区 医学 Q3 ONCOLOGY
Giuseppe Garofano, Cesare Saitta, Giacomo Musso, Margaret F Meagher, Umberto Capitanio, Dhruv Puri, Mai Dabbas, Natalie Birouty, Kit L Yuen, Alessandro Larcher, Benjamin Baker, Riccardo Autorino, Savio D Pandolfo, Francesco Montorsi, Giovanni Lughezzani, Paolo Casale, Nicolò M Buffi, Ithaar H Derweesh
{"title":"Nomogram for predicting long-term survival in renal cell carcinoma patients undergoing thermal ablation.","authors":"Giuseppe Garofano, Cesare Saitta, Giacomo Musso, Margaret F Meagher, Umberto Capitanio, Dhruv Puri, Mai Dabbas, Natalie Birouty, Kit L Yuen, Alessandro Larcher, Benjamin Baker, Riccardo Autorino, Savio D Pandolfo, Francesco Montorsi, Giovanni Lughezzani, Paolo Casale, Nicolò M Buffi, Ithaar H Derweesh","doi":"10.1016/j.urolonc.2025.04.012","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Thermal Ablation (TA) represents a valid option for management of renal cortical neoplasms. Recognizing paucity of tools to predict overall survival (OS) for patients undergoing TA, we developed a nomogram to offer personalized OS predictions utilizing the National Cancer Database.</p><p><strong>Methods: </strong>We included patients diagnosed with primary renal tumors who underwent TA between 2004 and 2020. Cox proportional hazards (CPH) model included age, Charlson-Deyo Comorbidity Index (CCI), tumor size, insurance status, ethnicity, histology, and tumor grade. A nomogram was developed to predict OS at 1, 5, and 10 years using a multivariable CPH model. Model robustness was confirmed through bootstrap validation with 1,000 iterations. Model performance was evaluated using Harrell's C-index, calibration plots at 1, 5, and 10 years, and time-dependent area under the curve (AUC) from ROC curves for 1-, 5-, and 10-year OS predictions RESULTS: We identified 10,121 patients (median age: 69 years; median follow-up: 55 months). Significant predictors of worse OS included advanced age (Hazard Ratio [HR] = 1.04, P < 0.001), higher CCI (HR = 2.20, P < 0.001), larger tumor size (HR = 1.03, P < 0.001), non-private insurance (HR = 2.16, P < 0.001), high-grade (HR = 1.31, P < 0.001), and clear cell (HR = 1.14, P = 0.015). Bootstrap validation confirmed the stability of the model, which achieved a C-index of 0.68. Calibration plots showed agreement between predicted and observed survival probabilities at 1, 5, and 10 years, with AUC values of 0.70, 0.71, and 0.74, respectively.</p><p><strong>Conclusion: </strong>We constructed a nomogram incorporating clinical, pathological, and socioeconomic factors to offer personalized OS prediction for TA. Future research should focus on external validation and clinical implementation.</p>","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":" ","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Urologic Oncology-seminars and Original Investigations","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.urolonc.2025.04.012","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: Thermal Ablation (TA) represents a valid option for management of renal cortical neoplasms. Recognizing paucity of tools to predict overall survival (OS) for patients undergoing TA, we developed a nomogram to offer personalized OS predictions utilizing the National Cancer Database.

Methods: We included patients diagnosed with primary renal tumors who underwent TA between 2004 and 2020. Cox proportional hazards (CPH) model included age, Charlson-Deyo Comorbidity Index (CCI), tumor size, insurance status, ethnicity, histology, and tumor grade. A nomogram was developed to predict OS at 1, 5, and 10 years using a multivariable CPH model. Model robustness was confirmed through bootstrap validation with 1,000 iterations. Model performance was evaluated using Harrell's C-index, calibration plots at 1, 5, and 10 years, and time-dependent area under the curve (AUC) from ROC curves for 1-, 5-, and 10-year OS predictions RESULTS: We identified 10,121 patients (median age: 69 years; median follow-up: 55 months). Significant predictors of worse OS included advanced age (Hazard Ratio [HR] = 1.04, P < 0.001), higher CCI (HR = 2.20, P < 0.001), larger tumor size (HR = 1.03, P < 0.001), non-private insurance (HR = 2.16, P < 0.001), high-grade (HR = 1.31, P < 0.001), and clear cell (HR = 1.14, P = 0.015). Bootstrap validation confirmed the stability of the model, which achieved a C-index of 0.68. Calibration plots showed agreement between predicted and observed survival probabilities at 1, 5, and 10 years, with AUC values of 0.70, 0.71, and 0.74, respectively.

Conclusion: We constructed a nomogram incorporating clinical, pathological, and socioeconomic factors to offer personalized OS prediction for TA. Future research should focus on external validation and clinical implementation.

预测热消融肾细胞癌患者长期生存的Nomogram。
目的:热消融(TA)是治疗肾皮质肿瘤的有效选择。认识到缺乏预测TA患者总生存期(OS)的工具,我们开发了一个nomogram,利用国家癌症数据库提供个性化的OS预测。方法:我们纳入了2004年至2020年间接受TA治疗的原发性肾肿瘤患者。Cox比例风险(CPH)模型包括年龄、Charlson-Deyo共病指数(CCI)、肿瘤大小、保险状况、种族、组织学和肿瘤分级。使用多变量CPH模型,开发了一种nomogram来预测1、5和10年的OS。通过1000次迭代的自举验证,验证了模型的稳健性。采用Harrell’s c指数、1年、5年和10年的校准图以及ROC曲线的曲线下时间依赖面积(AUC)对1年、5年和10年OS预测进行模型性能评估。结果:我们确定了10,121例患者(中位年龄:69岁;中位随访:55个月)。较差OS的显著预测因素包括高龄(风险比[HR] = 1.04,P )。结论:我们构建了一个结合临床、病理和社会经济因素的nomogram预测TA的OS。未来的研究应侧重于外部验证和临床实施。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.80
自引率
3.70%
发文量
297
审稿时长
7.6 weeks
期刊介绍: Urologic Oncology: Seminars and Original Investigations is the official journal of the Society of Urologic Oncology. The journal publishes practical, timely, and relevant clinical and basic science research articles which address any aspect of urologic oncology. Each issue comprises original research, news and topics, survey articles providing short commentaries on other important articles in the urologic oncology literature, and reviews including an in-depth Seminar examining a specific clinical dilemma. The journal periodically publishes supplement issues devoted to areas of current interest to the urologic oncology community. Articles published are of interest to researchers and the clinicians involved in the practice of urologic oncology including urologists, oncologists, and radiologists.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信